Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Kezar Life Sciences, Inc. (KZR)
Last kezar life sciences, inc. earnings: 8/7 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of topline data in mid-2025 KZR-261 dose expansion currently enrolling patients with melanoma; initial study data by year-end Cash, cash equivalents and marketable securities totaled $179.8 million as of March 31, 2024 SOUTH SAN FRANCISCO, Calif., May 09, 2024 BUSINESS WIRE Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. "We continued to make meaningful progress this past quarter on our mission to develop first-in-class small molecule therapeutics in immunology and oncology. We are focused this year on clinical execution in our PALIZADE and PORTOLA trials and are excited by the strong enrollment activity we h
Show less
Read more
Impact Snapshot
Event Time:
KZR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZR alerts
High impacting Kezar Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
KZR
News
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business Wire
KZR
Earnings
- 5/9/24 - Beat
KZR
Analyst Actions
- 5/10/24 - HC Wainwright
KZR
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/26/24 - Form ARS
- KZR's page on the SEC website